Real-World Outcomes of Adjuvant Therapy in Stage III Melanoma and the Impact of Somatic Mutations.

ABSTRACT:

Purpose

A significant proportion of patients with locoregional (stage III) cutaneous melanoma recur despite adjuvant systemic therapy. Staging criteria and surgical nodal management have changed since the trials were completed. Data assessing the effect of systemic therapy compared to surveillance are limited, and factors associated with recurrence are unclear. We assessed the efficacy of adjuvant systemic therapy in real-world patients and assessed whether baseline genomic characteristics could prognosticate or predict benefit from therapy.

Methods

We collected demographic, histopathologic, clinical, and genomic data for patients diagnosed with stage III cutaneous melanoma. Outcomes of interest were recurrence-free survival (RFS) and distant-metastasis-free survival (DMFS).

SUBMITTER: Effiom D 

PROVIDER: S-EPMC12676251 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature